References
- VandenDriessche T, Pipe SW, Pierce GF, et al. First conditional marketing authorization approval in the European Union for hemophilia “A” gene therapy. Mol Ther Internet. 2022 [cited 2023 Jul 30];30(11):3335–3336. doi: 10.1016/j.ymthe.2022.09.020
- Herzog RW, VandenDriessche T, Ozelo MC. First hemophilia B gene therapy approved: more than two decades in the making. Mol Ther Internet. 2023 [cited 2023 Jul 30]; 31(1):1–2. doi: 10.1016/j.ymthe.2022.12.001
- Kaczmarek R. Gene therapy - are we ready now? Haemophilia Internet. 2022 [cited 2023 Jul 30]; 28(Suppl 4):35–43. doi: 10.1111/hae.14530
- Kaczmarek R, Pierce GF, Noone D, et al. Eliminating Panglossian thinking in development of AAV therapeutics. Mol Ther Internet. 2021 [cited 2021 Dec 6];29(12):3325–3327. doi: 10.1016/j.ymthe.2021.10.025
- Pierce GF, Herzog RW. Two gene therapies for hemophilia available: Now what? Mol Ther Internet. 2023;31(4):919–920. doi: 10.1016/j.ymthe.2023.03.001
- Valentino LA, Kaczmarek R, Pierce GF, et al. Hemophilia gene therapy: first, do no harm. J Thromb Haemost Internet. 2023 [cited 2023 Jul 30];21(9):2354–2361. doi: 10.1016/j.jtha.2023.06.016
- Samelson-Jones BJ, George LA. Adeno-associated virus gene therapy for hemophilia. Annu Rev Med. 2023;74(1):231–247. doi: 10.1146/annurev-med-043021-033013
- Nathwani AC, Reiss U, Tuddenham E, et al. Adeno-associated mediated gene transfer for hemophilia B: 8 year follow up and impact of removing empty viral particles on safety and efficacy of gene transfer. Blood Internet. 2018 [cited 2023 Sep 5];132(Supplement 1):491–491. doi: 10.1182/blood-2018-99-118334
- von Drygalski A, Gomez E, Giermasz A, et al. Stable and durable factor IX levels in hemophilia B patients over 3 years post etranacogene dezaparvovec gene therapy. Blood Adv Internet. 2022 [cited 2023 Sep 5];7(19):5671–5679. doi: 10.1182/bloodadvances.2022008886
- George LA, Monahan PE, Eyster ME, et al. Multiyear factor VIII expression after AAV gene transfer for hemophilia a. N Engl J Med Internet. 2021 [cited 2023 Aug 2];385(21):1961–1973. doi: 10.1056/NEJMoa2104205
- Kaczmarek R, Herzog RW. Treatment-induced hemophilic thrombosis?. Mol Ther Internet. 2022 [cited 2023 Jul 30]; 30(2):505–506. doi: 10.1016/j.ymthe.2022.01.015
- Mahlangu J, Kaczmarek R, von Drygalski A, et al. Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia a. N Engl J Med Internet. 2023 [cited 2023 Aug 2];388(8):694–705. doi: 10.1056/NEJMoa2211075
- Pipe SW, Leebeek FWG, Recht M, et al. Gene therapy with Etranacogene Dezaparvovec for hemophilia B. N Engl J Med Internet. 2023 [cited 2023 Aug 2];388(8):706–718. doi: 10.1056/NEJMoa2211644
- Butterfield JSS, Yamada K, Bertolini TB, et al. IL-15 blockade and rapamycin rescue multifactorial loss of factor VIII from AAV-transduced hepatocytes in hemophilia a mice. Mol Ther. 2022;30(12):3552–3569. doi: 10.1016/j.ymthe.2022.07.005
- Brown HC, Fraser Wright J, Zhou S, et al. Bioengineered coagulation factor VIII enables long-term correction of murine hemophilia a following liver-directed adeno-associated viral vector delivery. Mol Ther Methods Clin Dev Internet. 2014 [cited 2021 Dec 10];1:14036. doi: 10.1038/mtm.2014.36
- Valentino LA, Ozelo MC, Herzog RW, et al. A review of the rationale for gene therapy for hemophilia a with inhibitors: one-shot tolerance and treatment? J Thromb Haemost Internet. 2023 [cited 2023 Aug 2]; doi: 10.1016/j.jtha.2023.05.011
- Pipe SW, Gonen-Yaacovi G, Segurado OG. Hemophilia a gene therapy: current and next-generation approaches. Expert Opin Biol Ther Internet. 2022 [cited 2023 Aug 2]; 22(9):1099–1115. doi: 10.1080/14712598.2022.2002842
- Huang H, Moroski-Erkul C, Bialek P, et al. CRISPR/Cas9-mediated targeted insertion of human F9 achieves therapeutic circulating protein levels in mice and non-human primates. 22nd Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) [InterCnet]. Washington, DC: Academic Press; 2019 cited 2019 Oct 24. Available from: http://apps.webofknowledge.com/full_record.do?product=WOS&search_mode=GeneralSearch&qid=1&SID=7BiFtAkFzlVog9YqCxn&page=1&doc=1.
- Truong B, Hajj K, Nguyen G, et al. Expression and activity of human factor VIII (hFVIII) following single and repeat administration of an integrating non-viral gene therapy in multiple mouse models of severe hemophilia a. ISTH Congress Internet. 2023 [cited 2023 Sep 5. Available from]; https://isth2023.eventscribe.net/agenda.asp?startdate=6/26/2023&enddate=6/26/2023&BCFO=&pfp=FullSchedule&mode=&fa=&fb=&fc=&fd=